trending Market Intelligence /marketintelligence/en/news-insights/trending/qcKMTZlpjrj9zX80DUYJ8w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Aurobindo recalls 1 lot of depressive disorder tablets due to label error

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Aurobindo recalls 1 lot of depressive disorder tablets due to label error

Aurobindo Pharma USA Inc. recalled one lot of its mirtazapine tablets due to a label error on the medicine's declared strength.

The voluntary recall was made as 7.5-milligram mirtazapine bottles may contain 15-milligram tablets, the U.S. Food and Drug Administration said in a news release.

Mirtazapine is used for treating major depressive disorder. Taking a higher dose of the drug than expected may increase the risk of sedation, agitation, increased reflexes, tremor, sweating, dilated pupils, gastrointestinal distress, nausea, constipation and other effects.

Aurobindo Pharma USA is also notifying its distributors and is arranging for the return of all of the recalled product.

Aurobindo Pharma USA is the U.S. unit of Indian pharmaceutical company Aurobindo Pharma Ltd.